基本情報
研究キーワード
4研究分野
1委員歴
5-
2012年 - 2014年
-
2014年
-
2014年
-
2014年
-
2012年
受賞
7-
2010年3月
-
2009年5月
-
2006年11月
-
2002年7月
論文
965-
Journal of the American Heart Association 14(2) e034627 2025年1月21日BACKGROUND: The effect of worsening renal function and baseline chronic kidney disease (CKD) on outcomes in patients with chronic coronary syndrome in the setting of optimal medical therapy remains unknown. METHODS AND RESULTS: The REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) study is a prospective, multicenter, randomized trial of high-dose (pitavastatin 4 mg/day) or low-dose (pitavastatin 1 mg/day) statin therapy in 12 118 patients with chronic coronary syndrome. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or unstable angina requiring hospitalization (major adverse cardiac and cerebral events [MACCE]). CKD was defined as an estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2. WRF was defined as a decrease in eGFR ≥20% in the initial year; borderline renal function was an annual decrease of 0%<eGFR<20%, and stable renal function was no decrease. Of 12 118 patients, 4340 had baseline CKD and 7778 did not. The rate of MACCE at 5 years was significantly lower in those without (5.5%) versus with CKD (9.5%) (P<0.0001). After excluding 1247 patients who had MACCE, were censored, or missing eGFR within 1 year, 10 871 patients were included. Of these, 3885 were baseline CKD and the remaining 6986 did not have baseline CKD. Of the 10 871 patients, 577 patients had WRF, 6014 patients showed borderline renal function, and the remaining 4280 patients maintained stable renal function. In patients with CKD, WRF was an independent predictor for MACCE at 4 years as compared with stable renal function (hazard ratio [HR]: 1.67; [95% CI, 1.03-2.73; P=0.039]). In patients without CKD, borderline renal function was a significant predictor for MACCE at 4 years compared with stable renal function (HR: 1.40 [95% CI, 1.03-1.91; P=0.032]). CONCLUSIONS: Baseline CKD was an independent predictor for MACCE in patients with CCS. WRF was a significant predictor for MACCE in patients with CKD. Because borderline renal function was an independent predictor for MACCE even in patients without CKD, mild-to-moderate annual declines of eGFR should be carefully monitored (NCT01042730). REGISTRATION: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT01042730.
-
International Journal of Molecular Sciences 26(2) 556-556 2025年1月10日 査読有り
-
IJC Heart & Vasculature 54 101507-101507 2024年10月
-
Hypertension research : official journal of the Japanese Society of Hypertension 2024年9月19日The Japanese Society of Hypertension have established a blood pressure (BP) target of 130/80 mmHg for patients with coronary artery disease (CAD). We evaluated the data of 8793 CAD patients in the Clinical Deep Data Accumulation System database who underwent cardiac catheterization at six university hospitals and the National Cerebral and Cardiovascular Center (average age 70 ± 11 years, 78% male, 43% with acute coronary syndrome [ACS]). Patients were divided into two groups based on whether or not they achieved the guideline-recommended BP of <130/80 mmHg. We analyzed the relationship between BP classification and major adverse cardiac and cerebral event (MACCE) separately in two groups: those with ACS and those with chronic coronary syndrome (CCS). During an average follow-up period of 33 months, 710 MACCEs occurred. A BP below 130/80 mmHg was associated with fewer MACCEs in both the overall (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.70-1.00, p = 0.048) and the ACS group (HR 0.67, 95%CI 0.51-0.88, p = 0.003). In particular, stroke events were also lower among those with a BP below 130/80 mmHg in both the overall (HR 0.69, 95%CI 0.53-0.90, p = 0.006) and ACS groups (HR 0.44, 95%CI 0.30-0.67, p < 0.001). In conclusion, the achievement of BP guidelines was associated with improved outcomes in CAD patients, particularly in reducing stroke risk among those with ACS.
MISC
1913-
日本心臓病学会誌 7(Suppl.I) 186-186 2012年8月
-
日本癌学会総会記事 71回 443-444 2012年8月
-
Expert opinion on therapeutic targets 16(8) 783-9 2012年8月 査読有りINTRODUCTION: Although 100,000 cardiac transplants have been performed, coronary allograft vasculopathy (CAV), which is a phenomenon of chronic rejection, is still a serious problem. AREAS COVERED: Several adhesion molecules, cytokines, and chemokines play a critical role in the process. Recent investigations have proved some promising methodologies for preventing or treating rejection. Although immunoglobulins are known to be an effective treatment in many diseases, their effect on cardiac transplantation or CAV is to be elucidated. EXPERT OPINION: In this review article, we described some promising methodologies that use immunoglobulins to prevent CAV. Immunoglobulins may be used to prevent CAV.
-
CURRENT TOPICS IN MEDICINAL CHEMISTRY 12(15) 1608-1612 2012年8月Although organ transplantations have been broadly performed in humans, occurrence of rejection has not yet been resolved. Several inflammatory factors, such as cytokines and adhesion molecules, enhance the rejection. Specific treatments that target in the attenuation of rejection have not been well studied in organ transplantation. Recent progress in the nucleic acid drugs, such as antisense oligodeoxynucleotides (ODNs) to regulate the transcription of disease-related genes, are known to play critical roles in therapeutic applications. Transfection of cis-element double-stranded DNA, named as "decoy", has been also reported to be a useful nucleic acid drug. This strategy has been not only a useful method for the experimental studies of gene regulation but also a novel clinical strategy. In this article, we reviewed the experimental results of nucleic acid drugs using the experimental organ transplant models.
-
INTERNATIONAL HEART JOURNAL 53(3) 208-208 2012年5月
-
Annals of Hematology 91(3) 467-468 2012年3月
-
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 59(13) E1035-E1035 2012年3月
-
JOURNAL OF PHARMACOLOGICAL SCIENCES 118 23P-23P 2012年
-
Journal of Arrhythmia 28(4) 242-246 2012年Immunoglobulin light chain (AL) amyloidosis has poor long-term prognosis. Sudden cardiac death (SCD) is a common cause of death in patients with cardiac AL amyloidosis. Prophylactic anti-arrhythmic device therapy has been suggested as an option to reduce this risk. We address this issue by reviewing 4 cases of cardiac AL amyloidosis with anti-arrhythmic device therapy. One patient who had an atrioventricular block underwent pacemaker implantation, and the other 3 patients received implantable cardioverter-defibrillator (ICD) implantation for ventricular arrhythmia. All of the 3 ICD implantation cases received appropriate shock therapy for ventricular arrhythmia in the early stage. However, they soon died due to pulseless electrical activity (PEA) or severe heart failure. The median survival period for our 4 cases was as short as 12.3 months. In particular, the 3 patients who required ICD had worse prognoses. Thus, ICD implantation therapy for chemotherapy-resistant cardiac AL amyloidosis may prevent SCD but may not prolong the patient's survival. There are no arguments against pacemaker implantation for cardiac amyloidosis with conduction disturbance however, the clinical benefit of ICD indication for ventricular tachyarrhythmia is limited. Further extensive clinical research should be performed to definitively determine the effects of ICD implantation on cardiac AL amyloidosis. © 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
CIRCULATION 124(21) 2011年11月
-
日本高血圧学会総会プログラム・抄録集 34th 396 2011年10月20日
-
New England Journal of Medicine 365(15) 1448-1450 2011年10月13日
-
Expert opinion on therapeutic targets 15(10) 1163-72 2011年10月 査読有りINTRODUCTION: Although prognosis in acute myocarditis is generally moderate, giant cell myocarditis shows poor prognosis. Giant cell myocarditis is considered to be an autoimmune disease, however, its pathophysiology and specific treatment is yet to be elucidated. AREAS COVERED: This article reviews the clinical characteristics of autoimmune myocarditis and its possible future treatments. An animal model of experimental autoimmune myocarditis (EAM) is characterized by severe myocardial damage and multinucleated giant cell infiltration, and this has been used as a disease model for human acute giant cell myocarditis. Using experimental models, we reported that NF-κB, cytokines, adhesion molecules and other factors play a critical role in the development of autoimmune myocarditis. EXPERT OPINION: Giant cell myocarditis, an autoimmune form of myocarditis, has a high mortality rate unless mechanical support or cardiac transplantation is performed. Therefore, further therapeutic applications of novel methodologies are needed to expand the number of alternative choices for treating autoimmune myocarditis.
-
呼吸と循環 59(9) 939-942 2011年9月マルファン症候群は,骨格異常,眼異常,心血管異常など多くの器官に病変を引き起こす常染色体優性遺伝の全身性結合組織疾患である.以前より口腔内所見として,高口蓋,歯列不正などが知られている.近年,諸外国においてマルファン症候群と歯周病との関係が注目されてきており,日本人におけるマルファン症候群の実態調査としてGhent基準陽性20名のマルファン症候群症例につき歯周病罹患状態を評価した.現在歯数は27歯とほぼ保たれていたが,歯周ポケットの深さ(PD)は2.815±0.624mm,PD測定部位での出血の有無(BOP)は11.567±8.394%,地域歯周疾患指数(CPI)は中等度・重度に該当するコード3,4の症例が15名(75%)も認められた.以上よりマルファン症候群では,中等度から重度の歯周病が高頻度に認められマルファン症候群における歯周組織の脆弱性が示唆された.(著者抄録)
-
INTERNATIONAL HEART JOURNAL 52(5) 266-269 2011年9月Prostaglandin E2 (PGE(2)) is produced in inflammatory responses and regulates a variety of immunological reactions through 4 different receptor subtypes; EP 1, 2, 3 and 4. However, the precise role of each receptor in cardiovascular disease has not yet been elucidated. Enhanced expression of some EPs has been observed in clinical and experimental cardiovascular diseases. EP agonists have been developed to clarify the role of each receptor. Recently, we developed a novel selective agonist to examine the effects of EP4 on cardiac transplantation, myocardial ischemia, and myocarditis. Of note, a selective EP4 agonist attenuated inflammatory cytokines and chemokines via attenuation of macrophage activation in inflammatory heart diseases. In this review article, we discuss the effects of PGE(2) receptor agonists on the development of cardiovascular diseases. (Int Heart J 2011; 52: 266-269)
-
JOURNAL OF CARDIAC FAILURE 17(9) S128-S128 2011年9月
-
Journal of the American College of Cardiology 58(7) 775-775 2011年8月9日 査読有り
-
JOURNAL OF CARDIAC FAILURE 17(8) S96-S96 2011年8月
書籍等出版物
21-
Springer 2009年 (ISBN: 9784431877745)
-
Signal Transduction and Cardiac Hypertrophy (Naranjan S. Dhalla, Larry Hryshko, Elissavet Kardami, Pawan K. Singal, KLUWER ACADEMIC PUBLISHERS) 2003年
-
Signal Transduction and Cardiac Hypertrophy (Naranjan S. Dhalla, Larry Hryshko, Elissavet Kardami, Pawan K. Singal, KLUWER ACADEMIC PUBLISHERS) 2003年
-
Rapid Cycle Real-Time PCR : methods and applications 2001年
-
in"The Hypertrophied Heart" 2000年
共同研究・競争的資金等の研究課題
91-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 2020年7月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2018年6月 - 2023年3月